[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608450":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":37,"responsibleParty":51,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":20,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Oral Levocarnitine (L-Carnitine), 2970mg daily dose (990mg taken 3 times a day) for 3 months.",[13],"Drug: Levocarnitine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Levocarnitine","Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Chris McIntyre, MBBS DM","London Health Sciences Centre","PRINCIPAL_INVESTIGATOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Kathy Koyle","CONTACT","519-685-8500","x 56214","kathleen.koyle@lhsc.on.ca",{"name":34,"role":29,"phone":30,"phoneExt":35,"email":36},"Amy Freeman, RN","x 55981","amy.freeman@lhsc.on.ca",[38],{"facility":24,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":20},"RECRUITING","London","Ontario","N6A 5W9","Canada","CA",{"type":46,"coordinates":47},"Point",[48,49],-81.23304,42.98339,{"lat":49,"lon":48},{"type":25,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Chris McIntyre","Nephrologist","100608450","early-phase-1-oral-carnitine-in-heart-failure-patients-100608450",false,"NCT07201714","Oral Carnitine in Heart Failure Patients","Oral L-Carnitine Supplementation in Cardiorenal Heart Failure Patients","Inclusion Criteria:\n\n* Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome\n* Stage 1, 2, 3a, 3b, or 4 chronic kidney disease\n* Age ≥ 18 years\n* Able to speak and read English\n* Willing and able to provide consent\n\nExclusion Criteria:\n\n* Estimated GFR \\\u003C15 mL\u002Fmin\u002F1.73m2 or Stage 5 chronic kidney disease\n* Currently undergoing renal replacement therapy of any kind\n* Pregnant, breastfeeding or intending pregnancy\n* History of seizures of any type\n* Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone\n* Unable to provide consent","ALL","18 Years",{"count":64,"type":65},20,"ESTIMATED","INTERVENTIONAL",[68],"EARLY_PHASE1","Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.",[71,72],"Heart Failure","Carnitine Deficiency","2026-04-15",{"date":75,"type":76},"2026-04-20","ACTUAL",{"date":78,"type":76},"2025-11-12",{"date":80,"type":65},"2026-12-31",{"name":5,"class":6},1]